Investment Analysts’ Weekly Ratings Changes for Climb Bio (CLYM)

Climb Bio (NASDAQ: CLYM) has recently received a number of price target changes and ratings updates:

• 5/9/2026 – Climb Bio was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/8/2026 – Climb Bio had its price target raised by Wedbush from $15.00 to $17.00. They now have an “outperform” rating on the stock.
• 5/6/2026 – Climb Bio was given a new $21.00 price target by Robert W. Baird.
• 5/6/2026 – Climb Bio had its price target raised by BTIG Research from $8.00 to $19.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Climb Bio is now covered by Chardan Capital. They set a “buy” rating and a $22.00 price target on the stock.
• 4/21/2026 – Climb Bio had its price target raised by Oppenheimer Holdings, Inc. from $10.00 to $18.00. They now have an “outperform” rating on the stock.
• 4/20/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/15/2026 – Climb Bio is now covered by Mizuho. They set an “outperform” rating and a $18.00 price target on the stock.
• 4/15/2026 – Climb Bio is now covered by Mizuho. They set an “outperform” rating and a $18.00 price target on the stock.
• 4/8/2026 – Climb Bio had its “buy” rating reaffirmed by BTIG Research. They now have a $8.00 price target on the stock.
• 3/24/2026 – Climb Bio is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $26.00 price target on the stock.
• 3/23/2026 – Climb Bio was upgraded by B. Riley Financial, Inc. to “strong-buy”.
• 3/17/2026 – Climb Bio is now covered by Truist Financial Corporation. They set a “buy” rating and a $17.00 price target on the stock.
• 3/17/2026 – Climb Bio was upgraded by Truist Financial Corporation to “strong-buy”.

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.